Piccirillo Gianfranco, Moscucci Federica, Sciomer Susanna, Magrì Damiano
Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Policlinico Umberto I, "Sapienza'' University of Rome, 00161 Rome, Italy.
Department of Internal Medicine and Medical Specialties, Policlinico Umberto I, 00161 Rome, Italy.
Rev Cardiovasc Med. 2023 Jul 17;24(7):208. doi: 10.31083/j.rcm2407208. eCollection 2023 Jul.
Despite significant progress in the field of therapy and management, chronic heart failure (CHF) still remains one of the most common causes of morbidity and mortality, especially among the elderly in Western countries. In particular, frequent episodes of decompensation and, consequently, repeated hospitalizations represent an unsustainable burden for national health systems and the cause of worsening quality of life. CHF is more prevalent in elderly women, who often have "peculiar" clinical characteristics and a more preserved ejection fraction caused by endothelial dysfunction and micro-vessel damage. At the moment, noninvasive technologies that are able to remotely monitor these patients are not widely available yet, and clinical trials are underway to evaluate invasive remote sensors. Unfortunately, implantable devices for identifying decompensation are not the most practical solution in the majority of of patients with chronic heart failure. In particular, they are hypothesized to have the possibility of monitoring patients by pro-B-type natriuretic peptide, ventricular repolarization variability, and bioimpedance cardiography at the first point of care, but new technology and clinical trials must be planned to address the development and spread of these emergent possibilities.
尽管在治疗和管理领域取得了显著进展,但慢性心力衰竭(CHF)仍然是发病和死亡的最常见原因之一,尤其是在西方国家的老年人中。特别是,失代偿的频繁发作以及随之而来的反复住院,对国家卫生系统来说是一个难以承受的负担,也是生活质量恶化的原因。CHF在老年女性中更为普遍,她们通常具有“特殊”的临床特征,并且由于内皮功能障碍和微血管损伤导致射血分数保留得更多。目前,能够远程监测这些患者的非侵入性技术尚未广泛应用,并且正在进行临床试验以评估侵入性远程传感器。不幸的是,在大多数慢性心力衰竭患者中,用于识别失代偿的植入式设备并不是最实用的解决方案。特别是,据推测它们有可能在第一时间通过前B型利钠肽、心室复极变异性和生物阻抗心动图来监测患者,但必须规划新技术和临床试验,以应对这些新出现可能性的发展和推广。